Related Experiment Video
Updated: Jun 2, 2025
08:05
Murine Model of Allergen Induced Asthma
Published on: May 14, 2012
40.1K
Potential drug targets for asthma identified through mendelian randomization analysis.
Xingxuan Chen1, Yu Shang2, Danting Shen1
1Department of Pulmonary and Critical Care Medicine, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, China.
Respiratory Research
|January 13, 2025
Summary
This study identified seven proteins causally linked to asthma risk using Mendelian randomization. Proteins like ECM1 and Layilin show promise as novel therapeutic targets for asthma treatment.
Area of Science:
- Genetics
- Immunology
- Pharmacology
Background:
- Limited treatment options for moderate-to-severe asthma necessitate novel therapeutic targets.
- Molecular targeted drugs have advanced asthma care, but gaps remain for specific patient groups.
Purpose of the Study:
- To identify novel therapeutic drug targets for asthma using Mendelian randomization.
- To leverage large-scale genome-wide association studies (GWAS) for target discovery.
Main Methods:
- Utilized GWAS data from UK Biobank and FinnGen cohorts.
- Employed Mendelian randomization, Steiger filtering, and colocalization analysis.
- Constructed a protein-protein interaction network to explore drug associations.
Main Results:
- Identified seven proteins with causal links to asthma risk: IL1R1, IL7R, ECM1, CD200R1, ADAM19, IL-6 sRa, and Layilin.
- Observed increased asthma risk with higher levels of IL1R1, IL7R, ECM1, CD200R1, and IL-6 sRa.
- Found protective effects against asthma with higher levels of ADAM19 and Layilin; ECM1, IL-6 sRa, and Layilin shared genetic variation with asthma.
Conclusions:
- Established causal relationships between specific protein levels and asthma.
- Highlighted ECM1 and Layilin as potential novel drug targets for asthma.
- Emphasized the need for further research into the roles of these proteins in asthma pathogenesis.
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
241
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
241
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
236
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
236
01:29Asthma-I: Introduction
2.6K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.6K
01:26Asthma-II: Pathophysiology and Classification
2.6K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.6K
01:20Asthma: Pathogenesis and Management
346
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
346
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
231
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
231